Published by Ministry of Health, Labour and Welfare



Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions Carmustine

Non-proprietary name

Carmustine

Safety measure

Precautions should be revised in the package insert.

In the Important precautions section, the following text should be added (underlined parts are revised):

Air accumulation may occur at the implant site, and there have been reports of neurological symptoms. After the implantation of the drug, neurological symptoms, such as hemiplegia, aphasia, and disturbed consciousness, should be carefully monitored. If any abnormalities are observed, appropriate measures should be adopted.

Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>